Rankings
▼
Calendar
MDGL Q2 2017 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q2 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
-$8,000
Operating Income
-$8M
Net Income
-$8M
EPS (Diluted)
$-0.69
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$8M
Stock-Based Comp.
$676,000
Balance Sheet
Total Assets
$68M
Total Liabilities
$6M
Stockholders' Equity
$62M
Cash & Equivalents
$35M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
-$8,000
$0
—
Operating Income
-$8M
-$3M
-141.9%
Net Income
-$8M
-$3M
-190.1%
← FY 2017
All Quarters
Q3 2017 →